Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $81.33.
Several equities research analysts have recently issued reports on KROS shares. TD Cowen lowered Keros Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Oppenheimer dropped their price objective on Keros Therapeutics from $102.00 to $63.00 and set an "outperform" rating for the company in a report on Monday. Bank of America dropped their price objective on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. HC Wainwright dropped their price objective on Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a report on Friday, December 13th. Finally, Guggenheim cut Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday.
View Our Latest Report on Keros Therapeutics
Shares of Keros Therapeutics stock opened at $18.00 on Wednesday. The stock has a 50 day moving average of $57.46 and a 200 day moving average of $52.30. Keros Therapeutics has a 12 month low of $15.67 and a 12 month high of $73.00. The firm has a market cap of $729.13 million, a PE ratio of -3.45 and a beta of 1.20.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company's revenue was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.33) earnings per share. As a group, equities research analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC raised its position in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company's stock valued at $284,493,000 after purchasing an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC raised its position in shares of Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after acquiring an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. raised its position in shares of Keros Therapeutics by 6.3% in the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company's stock worth $68,772,000 after acquiring an additional 89,952 shares in the last quarter. Point72 Asset Management L.P. raised its position in shares of Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after acquiring an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP raised its position in shares of Keros Therapeutics by 22.5% in the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company's stock worth $48,959,000 after acquiring an additional 154,784 shares in the last quarter. 71.56% of the stock is owned by institutional investors.
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.